# Presentation: 113881

## NCI: AT RO: SATURDAY

**Opportunities and Priorities **
**Presentations: 15 min or less**
**Breakout sessions**
**Summary & Conclusions & Feedback**

## BREAKOUT GROUPS

**Group 1 - Head (Brain, H&N & Peds)**
** **
**Group 2 - Trunk (Breast, Lung & Upper Abd)**
** **
**Group 3 - Pelvis (Prostate, Cervix & Colon-Rectum)**

## GROUP 1

**Bharat Mittal: Leader **
**Kian Ang **
**Wally Curran**
**Tom Delaney **
**Jonathan Farr**
**Jim Galvin**
**Eric Hall**
**Ed Halperin**
**Larry Kun**
**Minesh Mehta**
**Tom Merchant**

## GROUP 2

**Ted Deweese : Leader**
**Michael Baumann**
**Hank Choy**
**Joseph Deasy **
**Beryl McCormick**
**Nancy Mendenhall**
**Jatinder Palta**
**James Purdy**
**Randy Ten Haken**
**Allan Thornton**
**Jim Cox**
**Radhe Mohan**

## GROUP 3

**Mary Gaspodarowicz  & Jeff Michalski: Leaders**
**Chuck Enke**
**Thomas Fitzgerald**
**David Jaffray**
**David Gaffney**
**Karin Haustermans**
**Cliff Ling**
**Howard Sandler**
**Bill Shipley**
**Anurag Singh**
**Jerry Slater**
**Chris Willet**

## My Take

**Photons, Protons**
**IMRT, SRS, SBRT, IGRT**
**Quality Assurance**
**Image guidance**
**Lung cancer**
**Prostate cancer**
**Head & Neck Cancer**
**Peds**

## GUIDELINES 

**Timer, Scribe and Presenter **
**Limit comments to 2 minutes or less**
**Try to have everybody voice opinions**
**Please allow everybody around the table to voice opinions at least once before commenting second time, so on so forth**
**Discussion and formulation: 120 min.**
**Summary and mock presentation among ****	****your group:30 min. **

## KEY QUESTION 1

**The raison d’etre for the advanced technologies is to increase the dose to the cancer without increasing toxicity, or deliver the same dose as conventional technology but with less toxicity. **
***QUESTION: In which cancers is there the most pressing need for new technology for increasing the dose or decreasing the toxicity?***

## KEY QUESTION 2

**Demonstrating improved ANTICIPATED dose distributions (in-silico or in phantoms) only generates the hypothesis that a new technology may be superior. To prove that hypothesis, we must demonstrate - by controlled clinical trials - a clinically meaningful increase in survival and/or decrease in toxicity.**
***QUESTION: What clinical trials are the most important for demonstrating a meaningful benefit to patients?***

## KEY QUESTION 3

**Demonstrating improved ACTUAL dose distribution in the patient could be useful in phase I/II trials.**
***QUESTION: What technological developments are required for demonstrating ACTUAL dose distribution in-vivo?****** ***

## KEY QUESTION 4

**Other clinical or biological intermediate end-points may be useful in clinical trials.**
***QUESTION: What might those intermediate end-points be (and what lessons have we learned regarding their pitfalls from PSA, etc?)***

## SUCCESSFUL MEETING

**Do we clearly understand the objectives of the meeting?**
**Are we focusing on relevant facts and keeping to the original objectives? **
**Are we using our time efficiently?**
**Are we working towards solutions and results?**

## SUMMARY, REC. & FEEDBACK

**Each group presentation: 10 -15 min**
**Q & A: 15 min**
**Feedback:**
**Overall impression**
**Best part of the workshop**
**What would you do to improve this kind of workshop?**
**Rate the performance of this group**